Clinical Trial: A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.

U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT07445971) titled 'A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.' on Feb. 10.

Brief Summary: This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics, anti-drug antibodies, and neutralizing activity of MDX2301 administered by intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes in healthy adults and adults at higher risk for severe COVID-19. Participants will receive single IV, IM, and SC doses of MDX2301 or placebo and a repeat IM or SC dose approximately 3 months apart of MDX2301 or placebo.

Study Start Date: March, 2026

Study Type: INTERVENTIONAL

Condi...